fMRI Cholinergic Mechanisms in Schizophrenia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT01191827
First received: August 27, 2010
Last updated: March 20, 2012
Last verified: March 2012
  Purpose

This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.


Condition
Schizophrenia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: fMRI Cholinergic Mechanisms in Schizophrenia

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Neuronal response during sensory gating [ Time Frame: Immediate ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: October 2008
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
2
Patients with schizophrenia treated with clozapine

Detailed Description:

This study will use functional magnetic resonance imaging (fMRI) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects with schizophrenia

Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • age 18-60 yrs

Exclusion Criteria:

  • claustrophobia
  • weight > 250 lbs
  • metal in body other than dental fillings
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01191827

Locations
United States, Colorado
VA Eastern Colorado Health Care System, Denver
Denver, Colorado, United States, 80220
Sponsors and Collaborators
Investigators
Principal Investigator: Jason R. Tregellas, PhD VA Eastern Colorado Health Care System, Denver
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT01191827     History of Changes
Other Study ID Numbers: MHBB-011-07F
Study First Received: August 27, 2010
Last Updated: March 20, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 15, 2014